1. Signaling Pathways
  2. GPCR/G Protein
  3. CaSR

CaSR

Calcium-sensing receptor

The extracellular CaSR (calcium-sensing receptor is a unique G protein-coupled receptor (GPCR) activated by extracellular Ca2+ and by other physiological cations including Mg2+, amino acids, and polyamines. CaSR is the most important master controller of the extracellular Ca2+ homeostatic system being expressed at high levels in the parathyroid gland, kidney, gut, and bone, where it regulates parathyroid hormone (PTH) secretion, vitamin D synthesis, and Ca2+ absorption and resorption, respectively. Gain and loss of function mutations in the CaSR are responsible for severe disturbances in extracellular Ca2+ metabolism.

The CaSR stimulates two major signal transduction cascades. The first is the Gq/11-phospholipase C (PLC)-mediated generation of inositol 1,4,5-trisphosphate (IP3), which induces a rapid rise in intracellular calcium (Ca2+i) concentrations. The second is the mitogen-activated protein kinases (MAPKs), such as extracellular signal-regulated kinases 1 and 2 (ERK1/2), which phosphorylate proteins mediating cytosolic signaling and translocate into the nucleus to activate transcription factors involved in cellular proliferation and differentiation. The CaSR has been shown to activate MAPK signaling in a manner that depends on the G proteins Gq/11, and Gi/o, which inhibits cyclic adenosine monophosphate (cAMP) synthesis, and by a potentially G protein-independent mechanism involving β-arrestin types 1 and 2.

CaSR Related Products (65):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-109106B
    (Rac)-Upacicalcet
    (Rac)-Upacicalcet is the racemate of Upacicalcet (HY-109106). Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT.
    (Rac)-Upacicalcet
  • HY-15106
    SB-423557
    Antagonist
    SB-423557 is an orally active calcium-sensing receptor (CaR) antagonist (IC50=520 nM), precursor of SB-423562 (IC50=73 nM). SB-423557 is well tolerated in human and increases plasma concentrations of exogenous parathyroid hormone (PTH) and stimulates bone formation.
    SB-423557
  • HY-70037S
    Cinacalcet-d3
    Agonist
    Cinacalcet-d3 is the deuterium labeled Cinacalcet. Cinacalcet (AMG 073) is an orally active, allosteric agonist of Ca receptor (CaR), used for cardiovascular disease treatment.
    Cinacalcet-d<sub>3</sub>
  • HY-14752
    Ronacaleret
    Antagonist
    Ronacaleret (SB 751689) is an orally active, potent, and selective calcium-sensing receptor (CaSR) antagonist that stimulates endogenous parathyroid hormone release from the parathyroid glands. Ronacaleret (SB 751689) is used for the study of postmenopausal osteoporosis.
    Ronacaleret
  • HY-139201C
    Poly-D-lysine hydrobromide (MW 1000-5000)
    Activator
    Poly-D-lysine hydrobromide (MW 1000-5000) (PDLHB (MW 1000-5000)) is a synthetic cationic polypeptide polymer commonly used as a cell adhesion promoter and surface coating molecule. Poly-D-lysine hydrobromide is also known as a calcium-sensing receptor (CaSR) agonist peptide.
    Poly-D-lysine hydrobromide (MW 1000-5000)
  • HY-177303
    AXT-914
    Inhibitor 98.83%
    AXT-914 is a Calcium-sensing receptor (CaSR) inhibitor. AXT-914 has antiviral activity against the coronavirus HCoV 229E and SARS-CoV2. AXT914 reduces cytosolic calcium signalling activity of CaSR mutations. AXT-914 can be used for Bartter syndrome type 5 and autosomal dominant hypocalcemia (ADH) and coronavirus infections research.
    AXT-914
  • HY-P4376
    Gamma-Glu-Abu
    Agonist
    Gamma-Glu-Abu is an agonist for calcium sensing receptor (CaSR), that activates the CaSR with an EC50 of 0.21 μM in HEK-293 cell.
    Gamma-Glu-Abu
  • HY-10167
    Tecalcet
    Modulator
    Tecalcet (R 568), an orally active calcimimetic compound, allosterically and positively modulates the calcium-sensing receptor (CaSR). Tecalcet (R 568) increases the sensitivity to activation by extracellular Ca2+.
    Tecalcet
  • HY-103320
    Calhex 231
    Antagonist
    Calhex 231 is a potent negative allosteric modulator that blocks (IC50 = 0.39 μM) increases in [3H]inositol phosphates elicited by activating the human wild-type CaSR transiently Ca2+-sensing receptor. Calhex 231 can be used in the study of traumatic hemorrhagic shock (THS) and diabetic cardiomyopathy (DCM).
    Calhex 231
  • HY-153258
    CaSR antagonist-1
    Antagonist
    CaSR antagonist-1 is a calcium sensing receptor (CaSR) antagonist with an IC50 value of 50 nM. CaSR antagonist-1 can be used for the research of disorders associated with abnormal bone or mineral homeostasis such as osteoporosis.
    CaSR antagonist-1
  • HY-W777503
    Calindol hydrochloride-13C,D2
    Calindol hydrochloride-13C,d2 is the deuterium and 13C labeled Calindol hydrochloride (HY-122819). Calindol hydrochloride is a positive allosteric modulator (PAM) of calcimimetic calcium-sensing receptor (CaSR) with an EC50 of 132 nM.
    Calindol hydrochloride-<sup>13</sup>C,D<sub>2</sub>
  • HY-14401B
    Encaleret sodium
    Antagonist
    Encaleret (CLTX-305) sodium is an orally active antagonist of the calcium-sensing receptor (CaSR), with an IC50 of 12 nM. Encaleret sodium exerts its effect by inhibiting the excessive activity of functional gain-of-function CaSR variants, and can restore blood calcium levels, promote the secretion of parathyroid hormone, improve magnesium and phosphorus metabolism, and increase urinary calcium excretion. Encaleret sodium can be used in the research of diseases such as osteoporosis and autosomal dominant hypocalcemia type 1.
    Encaleret sodium
  • HY-17613S
    Evocalcet-d4
    Activator
    Evocalcet-d4 (KHK7580-d4) is deuterium labeled Evocalcet. Evocalcet (KHK7580) is an orally active calcium sensing receptor (CaSR) agonist. Evocalcet inhibits the secretion of parathyroid hormone (PTH) from parathyroid gland cells. Evocalcet can be used for the research of hyperparathyroidism.
    Evocalcet-d<sub>4</sub>
  • HY-N0546R
    Ligustroflavone (Standard)
    Antagonist
    Ligustroflavone (Standard) is the analytical standard of Ligustroflavone (HY-N0546). This product is intended for research and analytical applications. Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis.
    Ligustroflavone (Standard)
  • HY-15105A
    SB-423562 hydrochloride
    Antagonist
    SB-423562 hydrochloride is a short-acting calcium-sensing receptor (CaR) antagonist. SB-423562 hydrochloride has the potential for osteoporosis research.
    SB-423562 hydrochloride
  • HY-W653978
    Cinacalcet-d4 hydrochloride
    Agonist
    Cinacalcet-d4 (AMG-073-d4) hydrochlorideis deuterium labeled Cinacalcet (hydrochloride). Cinacalcet hydrochloride (AMG-073 hydrochloride) is an orally active, allosteric agonist of Ca receptor (CaR), used for cardiovascular disease treatment.
    Cinacalcet-d<sub>4</sub> hydrochloride
  • HY-171446
    TAK-075
    Antagonist
    TAK-075 is an orally active CaSR antagonist with an IC50 value of 0.94 nM. TAK-075 can stimulate the transient secretion of parathyroid hormone (PTH) in rats and can effectively prevent a significant reduction in PTH secretion caused by the accumulation of active metabolites, maintaining the normal secretion pattern of PTH. TAK-075 can be used in the research of metabolic diseases and osteoporosis.
    TAK-075
  • HY-107773R
    GSK3004774 (Standard)
    Agonist
    GSK3004774 (Standard) is the analytical standard of GSK3004774 (HY-107773). This product is intended for research and analytical applications. GSK3004774 is a potent, nonabsorbable agonist of CaSR, with an pEC50 of 7.3, 6.6 and 6.5 for human, mouse and rat CaSR, respectively. GSK3004774 shows an EC50 of 50 nM for human CaSR.
    GSK3004774 (Standard)
  • HY-161113
    Z8554052021
    Activator
    Z8554052021 (compound 2021) is a potent CaSR and indeed GPCR positive allosteric modulator (PAM) with an EC50 of 3.3 nM. Z8554052021 has the potential for hyperparathyroidism research.
    Z8554052021
  • HY-10007R
    NPS-2143 (Standard)
    Antagonist
    NPS-2143 (Standard) is the analytical standard of NPS-2143 (HY-10007). This product is intended for research and analytical applications. NPS-2143 (SB-262470A), an orally active calcilytic agent, is a selective and potent calcium ion-sensing receptor (CaSR) antagonist. NPS-2143 (SB-262470A) blocks increases in cytoplasmic Ca2+ concentrations (IC50=43 nM) elicited by activating the Ca2+ receptor in HEK 293 cells expressing the human Ca2+ receptor.
    NPS-2143 (Standard)